Abbott Laboratories $ABT Shares Sold by Dorsey & Whitney Trust CO LLC

Dorsey & Whitney Trust CO LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 11.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,093 shares of the healthcare product maker’s stock after selling 12,598 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Abbott Laboratories were worth $12,165,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ABT. Freemont Management S.A. grew its position in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after acquiring an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab purchased a new position in Abbott Laboratories in the fourth quarter worth approximately $116,580,000. Thrivent Financial for Lutherans grew its position in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after acquiring an additional 48,286 shares during the period. Danica Pension Livsforsikringsaktieselskab purchased a new position in Abbott Laboratories in the third quarter worth approximately $185,640,000. Finally, Net Worth Advisory Group purchased a new position in Abbott Laboratories in the fourth quarter worth approximately $1,366,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on ABT shares. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Wednesday, April 22nd. The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Jefferies Financial Group decreased their price target on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Argus decreased their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Bank of America decreased their price target on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.09.

Abbott Laboratories Stock Down 2.3%

NYSE:ABT opened at $89.15 on Thursday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock’s fifty day moving average is $92.01 and its two-hundred day moving average is $108.39. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The stock has a market capitalization of $155.29 billion, a price-to-earnings ratio of 24.97, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Buying and Selling at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott continues to gain attention for its cancer diagnostics growth story, with the Exact Sciences acquisition expanding its diagnostics portfolio and supportive screening data improving the long-term outlook. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
• Positive Sentiment: Abbott also received a boost from news that it secured CE Mark for its Libre Duo dual glucose-ketone sensing technology, a potential growth driver in diabetes care. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
• Neutral Sentiment: ABT is being highlighted as a trending stock across financial media, suggesting rising investor interest but not necessarily a clear catalyst by itself. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyst commentary also noted Abbott as a blue-chip, defensive name for long-term portfolios, reinforcing its stability and dividend appeal rather than signaling a near-term earnings surprise. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
• Negative Sentiment: Despite the positive business updates, the stock has still been trading lower, reflecting broader selling pressure and investor caution after recent gains. Abbott (ABT) Dips More Than Broader Market: What You Should Know

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.